Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
Key Points
It aims to raise up to $200 million in the offering.
This will support its efforts to bring its top drug candidate to market.
- 10 stocks we like better than MoonLake Immunotherapeutics ›
MoonLake Immunotherapeutics (NASDAQ: MLTX) clearly wasn't immune to negative investor sentiment on Wednesday. The clinical-stage biotech's equity slumped by almost 6% during that trading session, mainly due to a secondary share issue announced by the company.
A potential $200 million move
Late Tuesday night, MoonLake announced the pricing of the share issue, adding that it had been upsized.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
MoonLake is floating 9 million class A ordinary shares at $20 apiece. Certain investors in the offering can also opt to purchase pre-funded warrants granting the right to obtain up to 1 million of those shares. The price of those warrants is slightly under that $20. The underwriters of the issue have been granted a 30-day option to collectively buy an additional 1.5 million shares.
MoonLake should garner $180 million to $200 million in gross proceeds from this offering. Previously, it was targeting a minimum of $150 million.
The company said it will use the funds raised to continue research and development, pre-commercialization, and commercialization activities for its leading drug candidate, sonelokimab. The medication, in late-stage development, is intended for multiple autoimmune indications.
Worried about dilution
MoonLake currently has just under 74.6 million of those shares outstanding, so the new issue is clearly dilutive.
Investors rarely react positively to dilution, but it's not unusual for a biotech in the final stages of drug development to go on the hunt for fresh funding. Few aspects of bringing a treatment to market are cheap or easy, after all. Instead of being spooked by dilution, I'd be encouraged by the fact that management is seeking capital for its sonelokimab efforts.
Should you buy stock in MoonLake Immunotherapeutics right now?
Before you buy stock in MoonLake Immunotherapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and MoonLake Immunotherapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $392,713!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,227,782!*
Now, it’s worth noting Stock Advisor’s total average return is 897% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 24, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
